<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363989">
  <stage>Registered</stage>
  <submitdate>4/04/2013</submitdate>
  <approvaldate>23/04/2013</approvaldate>
  <actrnumber>ACTRN12613000462785</actrnumber>
  <trial_identification>
    <studytitle>The Effect of Intranasal Dexmedetomidine  Premedication on the Minimum Alveolar Concentration of Sevoflurane for the Insertion of Laryngeal Mask Airway in children</studytitle>
    <scientifictitle>The Effect of Intranasal Dexmedetomidine Premedication on Reducing the Minimum Alveolar Concentration of Sevoflurane for the Insertion of Laryngeal Mask Airway in Children</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Induction and maintenance of general anaesthesia in children</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>GroupD1 received 1mcg/Kg intranasal dexmedetomidine premedication 45min before general anaesthesia; GroupD2 received 2mcg/Kg intranasal dexmedetomidine premedication 45min before general anaesthesia;the intervention and the participants will be monitored throughout the duration of the procedure with follow up ending 4 hours after the procedure has been completed </interventions>
    <comparator>Group P received intranasal saline premedication 45min before general anaesthesia;the intervention and the participants will be monitored throughout the duration of the procedure with follow up ending 4 hours after the procedure has been completed </comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine and compare the Minimum Alveolar Concentration  of sevoflurane for LMA insertion in children by using Dixon and Massey up and down method</outcome>
      <timepoint>At or one minute after LMA insertion</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>the incident of adverse events were recorded in each patient's diary/health record for the trial e.g.laryngospasm,gapping,cough</outcome>
      <timepoint>Timepoint: during the period of Inhalation induction</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>the incidence of emergence agitation was evauated by the Pediatric Anesthesia Emergence Delirium Scale (PAED)</outcome>
      <timepoint>Participants will be followed for duration of PACU stay,an expected average of 2h</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ramsay Sedation Score</outcome>
      <timepoint>after intranasal administration every 10min until 60min</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Parent Satisfaction was evauated by the VAS Scale(0-10)</outcome>
      <timepoint>at the time of children  discharge from PACU </timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>ASA 1 and 2 patients of either gender of the age 3- 7 years undergoing elective strabismus surgery under general anaesthesia which can be performed with LMA insertion </inclusivecriteria>
    <inclusiveminage>3</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>7</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria: airway malformations, clinical evidence of patients with difficult airway, asthma or any sign of upper respiratory tract infection.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Children were randomly allocated to one of the three groups to receive premedication either placbo (Group S), dexmedetomidine 1microg/kg (Group D1), or dexmedetomidine 2microg/kg (Group D2) in a double-blinded fashion according to random list generated by a computer. Allocation was concealed by the method of sealed opaque envelopes . </concealment>
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>the sample size of 28 patients of every patients was base on an alfa=0.05,Beta=0.8</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>25/04/2013</anticipatedstartdate>
    <actualstartdate>13/05/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate>28/11/2013</actualenddate>
    <samplesize>90</samplesize>
    <actualsamplesize>90</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>China</country>
      <state>Fujian Province</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Yusheng Yao</primarysponsorname>
    <primarysponsoraddress>No.134 Dongjie Street, Fuzhou, Fujian, China, 350001 </primarysponsoraddress>
    <primarysponsorcountry>China</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Yusheng Yao</fundingname>
      <fundingaddress>No.134 Dongjie Street, Fuzhou, Fujian, China, 350001 </fundingaddress>
      <fundingcountry>China</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Pro. Yangqin Chen</sponsorname>
      <sponsoraddress>No.134 Dongjie Street, Fuzhou, Fujian, China, 350001 </sponsoraddress>
      <sponsorcountry>China</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Sevoflurane is widely employed for inhalational induction of general anaesthesia in children.  There is increasing evidence that dexmedetomidine is an effective and safe sedative in children. Laryngeal mask airway is an useful device for pediatric anesthesia. The aim of the current study was to determine whether Intranasal dexmedetomidine premedication can reduce MAC of sevoflurane for an LMA insertion in children</summary>
    <trialwebsite />
    <publication>Intranasal dexmedetomidine premedication reduces minimum alveolar concentration of sevoflurane for laryngeal mask airway insertion and emergence delirium in children: a prospective, randomized, double-blind, placebo-controlled trial.
Yao Y, Qian B, Lin Y, Wu W, Ye H, Chen Y.
Paediatr Anaesth. 2015 May;25(5):492-8. doi: 10.1111/pan.12574. Epub 2014 Dec 8.
PMID: 25487567</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Ethics and Committee of Fujian Provincal Hospital</ethicname>
      <ethicaddress>No.134 Dongjie Street, Fuzhou, Fujian, China, 350001 </ethicaddress>
      <ethicapprovaldate>26/03/2013</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>10/01/2013</ethicsubmitdate>
      <ethiccountry>China</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Yusheng Yao</name>
      <address>No.134 Dongjie Street, Fuzhou, Fujian, China, 350001 </address>
      <phone>86-13559939629</phone>
      <fax />
      <email>fjyys@yahoo.com.cn</email>
      <country>China</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Yanqing Chen</name>
      <address>No.134 Dongjie Street, Fuzhou, Fujian, China, 350001 </address>
      <phone>86-591-87945073</phone>
      <fax />
      <email>eyao717@sina.com</email>
      <country>China</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Yusheng Yao</name>
      <address>No.134 Dongjie Street, Fuzhou, Fujian, China, 350001 </address>
      <phone>86-13559939629</phone>
      <fax />
      <email>fjyys@yahoo.com.cn</email>
      <country>China</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Yusheng Yao</name>
      <address>No.134 Dongjie Street, Fuzhou, Fujian, China, 350001 </address>
      <phone>86-13559939629</phone>
      <fax />
      <email />
      <country>China</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>